A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics

Cancer Discovery

Volumn 5, Issue 12, 2015, Pages 1296-1313

  Sadanandam, Anguraj ^a,b,c   Wullschleger, Stephan ^b   Lyssiotis, Costas A ^d,h   Grötzinger, Carsten ^e   Barbi, Stefano ^f   Bersani, Samantha ^f   Körner, Jan ^e   Wafy, Ismael ^b   Mafficini, Andrea ^f   Lawlo, Rita T ^f   Simbolo, Michele ^f   Asara, John M ^g   Bläker, Hendrik ^e   Cantley, Lewis C ^d   Wiedenmann, Bertram ^e   Scarpa, Aldo ^f   Hanahan, Douglas ^b  

^a SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^b EPFL   (Switzerland)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; AUTOTAXIN; CD31 ANTIGEN; DAXX PROTEIN; EPHRIN A3; GLYCOPROTEIN M6A; HEPATOCYTE NUCLEAR FACTOR 1BETA; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PYRUVIC ACID; SEMAPHORIN 3E; TRANSCRIPTION FACTOR GATA 6; TUBERIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARBON; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CARBON METABOLISM; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; LASER CAPTURE MICRODISSECTION; LIVER METASTASIS; METABOLISM; METASTASIS LIKE PRIMARY; MICROARRAY ANALYSIS; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEXT GENERATION SEQUENCING; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SPECIES DIFFERENCE; VASCULARIZATION; ANIMAL; CANCER GRADING; CLUSTER ANALYSIS; DISEASE MODEL; EMBRYOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLOMICS; METASTASIS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); NEUROENDOCRINE TUMORS; ORGANOGENESIS; PANCREAS; PANCREAS ISLET BETA CELL; PANCREATIC NEOPLASMS; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BIOMARKERS; CARBON; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-SECRETING CELLS; METABOLOMICS; MICE; MICE, TRANSGENIC; MICRORNAS; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; ORGANOGENESIS; PANCREAS; PANCREATIC NEOPLASMS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84960109620     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0068     Document Type: Article

References (69)

1. Hanahan D, Wagner EF, Palmiter RD . The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 2007; 21: 2258–70.
2. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315: 115–22.
3. Hanahan D. Dissecting multistep tumorigenesis in transgenic mice. Annu Rev Genet 1988; 22: 479–519.
4. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58–61.
5. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin- like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369: 414–8.
6. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190–3.
7. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004; 5: 443–53.
8. Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002; 1: 339–53.
9. Li L, Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 2013; 153: 86–100.
10. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220–31.
11. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008; 5: e19.
12. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299–309.
13. Bergers G, Hanahan D. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 2002; 67: 293–300.
14. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287–95.
15. Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010; 28: 4425–33.
16. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501–13.
17. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2011; 8: 54–64.
18. Bosman FT. Classification of tumours of the digestive system. In: Bosman FT, editor. WHO classification of tumours of the digestive system. Lyon, France: World Health Organization; 2010.
19. Sobin LH, Gospodarowicz MK, Wittekind CC, editors. TNM classifi-cation of malignant tumors. Oxford, UK: Wiley-Blackwell; 2009.
20. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717–51.
21. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824–33.
22. Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous ? Endocr Relat Cancer 2013; 20: 649–57.
23. de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol 2012; 9: 199–208.
24. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199–203.
25. Chun MG, Hanahan D. Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet 2010; 6: e1001120.
26. Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 2001; 29: 459–64.
27. Hager JH, Hodgson JG, Fridlyand J, Hariono S, Gray JW, Hanahan D. Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. Cancer Res 2004; 64: 2406–10.
28. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23: 2152–65.
29. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677–84.
30. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A 2004; 101: 4164–9.
31. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500–3.
32. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013: 19: 619–25.
33. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116–21.
34. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28: 245–55.
35. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118–27.
36. Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of systematic microarray data biases. Bioinformatics 2004; 20: 105–14.
37. Pieterman CR, Conemans EB, Dreijerink KM, de Laat JM, Timmers HT, Vriens MR, et al. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Endocr Relat Cancer 2014; 21: R121–42.
38. Cao Y, Gao Z, Li L, Jiang X, Shan A, Cai J, et al. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun 2013; 4: 2810.
39. Hunter KE, Quick ML, Sadanandam A, Hanahan D, Joyce JA. Identifi- cation and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis. PloS One 2013; 8: e64472.
40. Jorgensen MC, Ahnfelt-Ronne J, Hald J, Madsen OD, Serup P, Hecksher- Sorensen J. An illustrated review of early pancreas development in the mouse. Endocr Rev 2007; 28: 685–705.
41. Benitez CM, Goodyer WR, Kim SK. Deconstructing pancreas developmental biology. Cold Spring Harbor Perspect Biol 2012; 4: a012401.
42. Shyh-Chang N, Daley GQ. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell 2013; 12: 395–406.
43. Hang Y, Stein R. MafA and MafB activity in pancreatic beta cells. Trends Endocrinol Metab 2011; 22: 364–73.
44. Alpert S, Hanahan D, Teitelman G. Hybrid insulin genes reveal a developmental lineage for pancreatic endocrine cells and imply a relationship with neurons. Cell 1988; 53: 295–308.
45. Smukler SR, Arntfield ME, Razavi R, Bikopoulos G, Karpowicz P, Seaberg R, et al. The adult mouse and human pancreas contain rare multipotent stem cells that express insulin. Cell Stem Cell 2011; 8: 281–93.
46. Quintens R, Hendrickx N, Lemaire K, Schuit F. Why expression of some genes is disallowed in beta-cells. Biochem Soc Trans 2008; 36: 300–5.
47. Jensen MV, Joseph JW, Ronnebaum SM, Burgess SC, Sherry AD, Newgard CB. Metabolic cycling in control of glucose-stimulated insulin secretion. Am J Physiol Cell Physiol 2008; 295: E1287–97.
48. Lu D, Mulder H, Zhao P, Burgess SC, Jensen MV, Kamzolova S, et al. 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc Natl Acad Sci U S A 2002; 99: 2708–13.
49. Pongratz RL, Kibbey RG, Shulman GI, Cline GW. Cytosolic and mitochondrial malic enzyme isoforms differentially control insulin secretion. J Biol Chem 2007; 282: 200–7.
50. Efrat S, Linde S, Kofod H, Spector D, Delannoy M, Grant S, et al. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci U S A 1988; 85: 9037–41.
51. Yuan M, Breitkopf SB, Yang X, Asara JM. A positive/negative ionswitching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc 2012; 7: 872–81.
52. Sugden MC, Holness MJ. The pyruvate carboxylase-pyruvate dehydrogenase axis in islet pyruvate metabolism: Going round in circles ? Islets 2011; 3: 302–19.
53. Oberg K, Akerstrom G, Rindi G, Jelic S, Group EGW. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v223–7.
54. Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125: 1094–104.
55. Couvelard A, O’Toole D, Turley H, Leek R, Sauvanet A, Degott C, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005; 92: 94–101.
56. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, et al. Prognostic value of tumor architecture, tumorassociated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 2007; 13: 187–96.
57. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478–86.
58. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314–22.
59. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson M D, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2009; 17: 98–110.
60. de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol 2012; 25: 1033–9.
61. Parangi S, Dietrich W, Christofori G, Lander ES, Hanahan D. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res 1995; 55: 6071–6.
62. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
63. Bengtsson H, Simpson K, Bullard J, Hansen K. aroma.affymetrix: a generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory. In Tech Report #745. Berkeley, CA: Department of Statistics, University of California; 2008.
64. Pradervand S, Weber J, Thomas J, Bueno M, Wirapati P, Lefort K, et al. Impact of normalization on miRNA microarray expression profiling. RNA (New York, NY) 2009; 15: 493–501.
65. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
66. Sadanandam A, Wang X, de Sousa EMF, Gray JW, Vermeulen L, Hanahan D, et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 2014; 13: 353–7.
67. Sadanandam A, Varney ML, Singh S, Ashour AE, Moniaux N, Deb S, et al. High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer 2010; 127: 1373–83.
68. Sadanandam A, Sidhu SS, Wullschleger S, Singh S, Varney ML, Yang CS, et al. Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br J Cancer 2012: 107: 501–7.
69. Amato E, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014; 233: 217–27